Brain games may hold key to delaying dementia

NCT ID NCT03848312

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This trial tests whether a specific type of computerized cognitive training, called speed-of-processing training, can delay the onset of mild cognitive impairment or dementia in adults aged 65 and older. Participants will complete 45 sessions of either the training or a general cognitive stimulation program. The goal is to see if this brain exercise can help maintain cognitive health and independence in later life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Computerized cognitive training exercises
What this could lead to
If effective, this could offer a non-drug way to delay or prevent dementia and mild cognitive impairment in older adults, potentially improving quality of life and reducing healthcare costs.
What could go wrong
The trial is large but results are not yet known; cognitive training may not translate to real-world benefits, and adherence over three years could be challenging.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

7,600 people

The number who actually took part.

Started

Feb 2019

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Be age 65 or older at time of consent * Have ability to speak and understand English or Spanish * Report adequate sensorimotor capacity to perform the computer exercises * Report adequate visual capacity to read from a computer screen at a typical viewing distance * Show adequate auditory capacity to understand conversational speech * Show adequate motor capacity to touch a computer screen or control a computer mouse. * Have no evidence of Mild Cognitive Impairment (MCI) or dementia, as assessed by the Montreal Cognitive Assessment score \>=26. * Have adequate mental health (no self-reported diagnoses of mental illness that would interfere with ability to comply with study procedures or benefit from intervention) * Wiling to complete all study activities * Ability to understand study procedures and comply with them for the length of the study Exclusion Criteria: * Currently enrolled in another randomized clinical trial, treatment trial, or another research study that assesses cognition * Previous participation in a cognitive training study * Self-reported vision, hearing, or motor difficulties that would interfere with the ability to complete the study interventions * Self-reported diagnosis of mild cognitive impairment, dementia, stroke, traumatic brain injury, brain tumor, or a neurological disorder that affects cognition or would interfere with the ability to benefit from the study intervention (e.g., Parkinson disease, multiple sclerosis), or any other unstable medical conditions that is predisposing to imminent cognitive or functional decline (e.g., congestive heart failure, chronic obstructive pulmonary disorder dependent on oxygen, or undergoing chemotherapy or radiation). * Self-reported use of medications typically prescribed for dementia such as: Namenda, Memantine, Namzaric, Donepezil, Aricept, Rivastigmine, Exelon, Razadyne, Galantamine, Reminyl, aducanumab, Aduhlem. * Completion of 10 or more hours of a computerized cognitive training program in the last 5 years such as: Lumosity, Posit Science Brain Fitness, InSight, or Brain HQ, Lace, CogMed, CogniFit, Happy Neuron, Elevate, or Dakim * Severe depressive symptoms (Geriatric Depression Scale score \>=5)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related cognitive decline are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clemson University Institute for Engaged Aging

    Seneca, South Carolina, 29672, United States

  • Duke Health

    Durham, North Carolina, 27705, United States

  • The Roskamp Institute

    Sarasota, Florida, 34243, United States

  • University of Florida

    Gainesville, Florida, 32611, United States

  • University of Florida

    Jacksonville, Florida, 32209, United States

  • University of North Florida

    Jacksonville, Florida, 32224, United States

  • University of South Florida

    Tampa, Florida, 33620, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.